PDF(Pubmed)
Abstract：
UNASSIGNED: Intrahepatic cholangiocellular carcinoma (ICC) is one of the most common invasive malignancies. Currently, ICC is treated with radical surgical resection. However, the majority of patients are diagnosed at an advanced stage, making surgery ineligible for them.
UNASSIGNED: We present a case of advanced ICC, which could not undergo radical surgery due to tumor invasion of liver blood vessels. The gemcitabine and oxaliplatin (GEMOX) regimen combined with Tislelizumab immunotherapy and Lenvatinib targeted therapy for 8 cycles resulted in significant tumor shrinkage significantly and the vascular invasion disappeared. CA19-9 levels were reduced to normal levels. Partial remission and successful tumor transformation were achieved. The patient underwent a successful radical surgical resection, including cholecystectomy, resection of liver segments IV, V, and VIII, as well as a regional lymphatic dissection procedure, resulting in complete pathological remission.
UNASSIGNED: Tumor-free surgical margins (R0) resection of patients with advanced ICC after combination of immune, targeted and chemotherapy is rare, and there are almost no cases of complete postoperative remission. The GEMOX regimen in combination with Tislelizumab and Lenvatinib has a good antitumor efficacy and safety profile, and may be a feasible and safe translational treatment option for advanced ICC.
UNASSIGNED: We present a case of advanced ICC, which could not undergo radical surgery due to tumor invasion of liver blood vessels. The gemcitabine and oxaliplatin (GEMOX) regimen combined with Tislelizumab immunotherapy and Lenvatinib targeted therapy for 8 cycles resulted in significant tumor shrinkage significantly and the vascular invasion disappeared. CA19-9 levels were reduced to normal levels. Partial remission and successful tumor transformation were achieved. The patient underwent a successful radical surgical resection, including cholecystectomy, resection of liver segments IV, V, and VIII, as well as a regional lymphatic dissection procedure, resulting in complete pathological remission.
UNASSIGNED: Tumor-free surgical margins (R0) resection of patients with advanced ICC after combination of immune, targeted and chemotherapy is rare, and there are almost no cases of complete postoperative remission. The GEMOX regimen in combination with Tislelizumab and Lenvatinib has a good antitumor efficacy and safety profile, and may be a feasible and safe translational treatment option for advanced ICC.
摘要：
■肝内胆管细胞癌（ICC）是最常见的侵袭性恶性肿瘤之一。目前,ICC采用根治性手术切除治疗。然而,大多数患者被诊断为晚期，让手术不适合他们。
■我们提出了一个先进的ICC案例，由于肿瘤侵入肝血管而无法进行根治性手术。吉西他滨和奥沙利铂（GEMOX）方案联合Tislelizumab免疫治疗和Lenvatinib靶向治疗8个周期，导致肿瘤明显缩小，血管浸润消失。CA19-9水平降低至正常水平。部分缓解，肿瘤转化成功。患者接受了一次成功的根治性手术切除,包括胆囊切除术,肝IV段切除术，V,VIII,以及局部淋巴解剖程序，导致病理完全缓解。
■晚期ICC患者联合免疫后无瘤手术切缘（R0）切除，靶向和化疗是罕见的，术后几乎没有完全缓解的病例。GEMOX方案联合Tislelizumab和Lenvatinib具有良好的抗肿瘤疗效和安全性，可能是一种可行和安全的转化治疗方案。
■我们提出了一个先进的ICC案例，由于肿瘤侵入肝血管而无法进行根治性手术。吉西他滨和奥沙利铂（GEMOX）方案联合Tislelizumab免疫治疗和Lenvatinib靶向治疗8个周期，导致肿瘤明显缩小，血管浸润消失。CA19-9水平降低至正常水平。部分缓解，肿瘤转化成功。患者接受了一次成功的根治性手术切除,包括胆囊切除术,肝IV段切除术，V,VIII,以及局部淋巴解剖程序，导致病理完全缓解。
■晚期ICC患者联合免疫后无瘤手术切缘（R0）切除，靶向和化疗是罕见的，术后几乎没有完全缓解的病例。GEMOX方案联合Tislelizumab和Lenvatinib具有良好的抗肿瘤疗效和安全性，可能是一种可行和安全的转化治疗方案。
